Rivas Capital

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Clarify Health Solutions, Inc. is a healthcare technology company based in San Francisco, California, that provides a software and analytics platform designed to enhance patient care delivery. The platform, known as Clarify Episode, facilitates real-time engagement among patients, clinicians, and care teams by delivering critical information and insights. It stratifies patients based on various characteristics, monitors their progress, and identifies potential complications early, prompting timely interventions. Key offerings include Care Pilot, a mobile and browser-based tool that empowers patients in their care journey; Care Connect, which enables clinicians to monitor and analyze patient data; and Care Prism, which delivers real-time business and productivity analytics for management. The company's solutions aim to improve efficiency, satisfaction, and engagement for patients, care teams, hospitals, and payers. Clarify Health Solutions was incorporated in 2015 and maintains a strategic alliance with Leidos.

NextRNA Therapeutics is a biotechnology company based in Cambridge, Massachusetts, founded in 2020. The company focuses on developing targeted therapeutics by discovering novel non-coding ribonucleic acids (ncRNAs) linked to various diseases. Utilizing an innovative discovery platform, NextRNA identifies and modulates RNA-binding proteins associated with disease functions of ncRNAs. This approach aims to disrupt the interactions between disease-related ncRNAs and their protein partners, thereby enabling medical practitioners to address and potentially cure a range of diseases.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Comgy GmbH, founded in 2017 and based in Berlin, Germany, specializes in digital metering solutions for the housing and energy sectors. The company offers a range of products including a sub-metering solution that enables users to efficiently read meters, alongside sensors and smoke alarms. Comgy provides a Meter Gateway Management application, which acts as a control center for remote device configuration and data processing, as well as a Meter Installation Manager application for the digital registration of radiator measurements, supported by photographic documentation. Additionally, its Polyglot gateway facilitates encrypted communication between meters, sensors, and its customer platform. Comgy's technology enhances the measurement, visualization, and billing processes of heat, water, and electricity consumption in real estate, promoting transparency and facilitating energy savings.

Inari is a biotechnology company focused on revolutionizing agriculture and its societal and environmental impact. The company utilizes advanced technologies, including predictive design and multiplex gene editing, to maximize the potential of seeds. Its unique SEEDesign platform distinguishes Inari by enabling the enhancement of various crops across different geographies, facilitating the development of innovative agricultural products. By embracing diversity, Inari fosters innovation and aims to contribute to the creation of a new food system.

Clarify Health Solutions, Inc. is a healthcare technology company based in San Francisco, California, that provides a software and analytics platform designed to enhance patient care delivery. The platform, known as Clarify Episode, facilitates real-time engagement among patients, clinicians, and care teams by delivering critical information and insights. It stratifies patients based on various characteristics, monitors their progress, and identifies potential complications early, prompting timely interventions. Key offerings include Care Pilot, a mobile and browser-based tool that empowers patients in their care journey; Care Connect, which enables clinicians to monitor and analyze patient data; and Care Prism, which delivers real-time business and productivity analytics for management. The company's solutions aim to improve efficiency, satisfaction, and engagement for patients, care teams, hospitals, and payers. Clarify Health Solutions was incorporated in 2015 and maintains a strategic alliance with Leidos.

Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Glympse Bio, Inc. is a biotechnology company based in Cambridge, Massachusetts, that specializes in developing modular nanoparticle sensors for noninvasive diagnostics. Founded in 2015, the company focuses on creating diagnostic solutions for various diseases, including fibrosis, cancer, immunology, and infectious diseases. Utilizing a unique platform technology originally developed at MIT, Glympse Bio employs precisely engineered diagnostic agents that interrogate the body to detect specific disease states and transmit this information to urine for analysis. This innovative approach facilitates predictive monitoring and enhances the ability of physicians to assess treatment responses accurately. The company aims to transform disease monitoring and improve patient outcomes through its Glympse Inside product engine, which supports comprehensive, pan-disease diagnostics.

Gamalon is an artificial intelligence company that develops machine intelligence technologies centered on Bayesian probabilistic programming. Founded in 2013 and based in Boston, the company builds a conversational machine intelligence platform that reads customer text, interprets and summarizes it, and makes predictions to help enterprises understand customer needs and take action. Its technology accelerates machine learning by enabling systems to write and rewrite Bayesian programs and convert streams of text into structured data rows through linking, allowing organizations to train models with limited data while achieving strong accuracy. By extracting insights from customer messages and enabling proactive actions, Gamalon aims to improve customer experiences and support informed decision making.

Kodiak Sciences is a biopharmaceutical company focused on developing novel therapies for retinal diseases. Its lead product candidate, KSI-301, targets wet age-related macular degeneration and diabetic retinopathy. The company's pipeline also includes KSI-501, targeting inflammation and abnormal angiogenesis in retinal vascular diseases, and KSI-601 for dry AMD.

ReviveMed develops a precision-medicine platform that transforms untargeted metabolomic data into actionable insights. Its network-based machine learning algorithm integrates metabolomics with other molecular information, facilitating the development of therapeutics for liver diseases.

GreenLight Biosciences is a biotechnology company specializing in RNA-based solutions for agriculture and pharmaceutical applications. It develops mRNA vaccines, including COVID-19 candidates, and offers sustainable crop protection technologies using its proprietary cell-free production platform.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Gamalon is an artificial intelligence company that develops machine intelligence technologies centered on Bayesian probabilistic programming. Founded in 2013 and based in Boston, the company builds a conversational machine intelligence platform that reads customer text, interprets and summarizes it, and makes predictions to help enterprises understand customer needs and take action. Its technology accelerates machine learning by enabling systems to write and rewrite Bayesian programs and convert streams of text into structured data rows through linking, allowing organizations to train models with limited data while achieving strong accuracy. By extracting insights from customer messages and enabling proactive actions, Gamalon aims to improve customer experiences and support informed decision making.

Gamalon is an artificial intelligence company that develops machine intelligence technologies centered on Bayesian probabilistic programming. Founded in 2013 and based in Boston, the company builds a conversational machine intelligence platform that reads customer text, interprets and summarizes it, and makes predictions to help enterprises understand customer needs and take action. Its technology accelerates machine learning by enabling systems to write and rewrite Bayesian programs and convert streams of text into structured data rows through linking, allowing organizations to train models with limited data while achieving strong accuracy. By extracting insights from customer messages and enabling proactive actions, Gamalon aims to improve customer experiences and support informed decision making.

Force of Nature manufactures electronic appliances designed to create a cleaning solution using basic ingredients found at home.

N12 Technologies, Inc. is a manufacturer of advanced nano-composite materials, specializing in production-scale nanotechnology for the aerospace, automotive, and consumer goods sectors. The company offers innovative products such as NanoStitch, which reinforces the interlaminar region of composite materials, and the Surface Layer System, designed to enhance thermal and electrical conductivity for various applications. N12's technology, developed through research licensed from MIT, utilizes vertically-aligned carbon nanotube (VACNT) forests to improve material properties such as shear strength, fatigue life, and impact resistance. This enables clients to achieve greater weight savings and toughness without altering existing fabrication processes. Founded in 2012, N12 Technologies is based in Somerville, Massachusetts, and serves a diverse range of industries, including sporting goods and aeronautics.

Zipline designs, manufactures, and operates drones for delivering vital medical products such as vaccines, medicines, and blood. Based in Half Moon Bay, California, Zipline aims to provide instant access to these supplies worldwide.

Aircuity, Inc. is a manufacturer of intelligent measurement solutions aimed at enhancing energy efficiency and indoor environmental quality in various settings, including commercial offices, educational institutions, healthcare facilities, and sports arenas. Founded in 2000 and headquartered in Newton, Massachusetts, the company offers a range of products, including the Sensor Suite, which utilizes a scalable architecture for monitoring multiple indoor environmental parameters. Their offerings also include specialized sensors for evaluating conditions such as temperature and air quality, along with a comprehensive Information Management System for network oversight. Aircuity's technology focuses on demand control ventilation, allowing for real-time adjustments based on internal conditions, thereby optimizing operational performance and safety. The company markets its products through various sales channels across numerous countries, ensuring a global reach in supporting energy conservation and improving indoor environments.

N12 Technologies, Inc. is a manufacturer of advanced nano-composite materials, specializing in production-scale nanotechnology for the aerospace, automotive, and consumer goods sectors. The company offers innovative products such as NanoStitch, which reinforces the interlaminar region of composite materials, and the Surface Layer System, designed to enhance thermal and electrical conductivity for various applications. N12's technology, developed through research licensed from MIT, utilizes vertically-aligned carbon nanotube (VACNT) forests to improve material properties such as shear strength, fatigue life, and impact resistance. This enables clients to achieve greater weight savings and toughness without altering existing fabrication processes. Founded in 2012, N12 Technologies is based in Somerville, Massachusetts, and serves a diverse range of industries, including sporting goods and aeronautics.

Lumicell, Inc. is a company focused on developing and marketing innovative image-guided solutions for cancer surgery. It specializes in technology that provides real-time visual feedback to surgeons regarding the presence of residual cancer cells within the tumor bed. The core of Lumicell's system includes a handheld imaging device and a cancer-specific optical contrast agent that illuminates cancer cells, allowing for thorough removal of cancerous tissue during surgery. The company's lead product is currently undergoing clinical trials, particularly in breast cancer surgery, where it aims to reduce the rates of positive margins and repeat surgeries while preserving healthy tissue. Additionally, Lumicell's technology is being explored for use in other types of cancer, such as colorectal cancer and pancreatic cancer. Founded in 2008 and based in Wellesley, Massachusetts, Lumicell has demonstrated a strong safety profile for its imaging agent and has not missed any cancer detections in clinical studies to date.